Protein-bound platinum complexes (Pt-protein adducts)

Protein-bound platinum complexes refer to the chemical species formed when platinum-based antineoplastic agents, such as cisplatin or oxaliplatin, covalently bind to plasma or cellular proteins. In the bloodstream, a significant portion (often >90%) of administered platinum drugs becomes irreversibly bound to proteins like albumin and transferrin, which serves to neutralize the drug's cytotoxic potential and facilitate its transport. While these complexes are not therapeutic targets themselves, they play a critical role in the pharmacokinetics and toxicology of platinum therapy. The formation of these adducts is generally viewed as a detoxification or inactivation pathway because the platinum is no longer available to form the DNA cross-links required for anti-tumor activity. However, the persistence of these complexes in the body is often associated with the long-term side effects of chemotherapy, including peripheral neuropathy and renal impairment. Understanding the ratio of free to protein-bound platinum is essential for optimizing dosing and managing the narrow therapeutic index of these agents.

Other names

Platinum-protein adductsAlbumin-bound platinumPlatinum-serum protein complexesPt-albumin complexesProtein-conjugated platinum

Protein-bound platinum complexes are formed when platinum-based chemotherapeutic agents react with the thiol or amino groups of proteins such as albumin and transferrin. While these complexes can act as a circulating reservoir for the drug, they are generally considered pharmacologically inactive compared to the free, 'unbound' platinum species that can enter cells and bind to DNA (the primary therapeutic target).